Arimidex
Product Images NDC 54868-5000

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Arimidex (NDC 54868-5000). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Arimidex 1mg (30 tablet count bottle label)

Label for ARIMIDEX 1 MG distributed by Physicians Total Care, Inc., Tulsa, OK. It shows the product NDC 54868-5000, lot number 0000, and an expiration date of 01/60. Manufactured by AstraZeneca LP, Wilmington, DE 19899. Includes a barcode at the bottom.*

FDA Label Image

Chemical Structure For Anastrozole (Arimidex Chem)

Chemical structure diagram of the active ingredient associated with ARIMIDEX, showing a benzene ring with attached cyano and methyl groups, and a triazole ring connected via a methylene bridge.*

FDA Label Image

Figure 5 (Arimidex Figurefive)

A Kaplan-Meier survival curve graph showing the proportion of patients not progressing over time in months. The graph compares two randomized treatments, labeled as Anastrozole (solid line) and Tamoxifen (dashed line), with a corresponding number of patients at risk listed below the x-axis at various time points up to 32 months.*

FDA Label Image

Figure 1 (Arimidex Figureone 01)

A line graph comparing disease-free survival over months between two treatments: anastrozole and tamoxifen. The y-axis represents the proportion of patients alive and disease-free, ranging from 0 to 1. The x-axis shows disease-free survival time in months, up to 90 months. A dashed line indicates anastrozole, and a solid line indicates tamoxifen. Below the graph, the number of patients at risk for each treatment is listed at various time points.*

FDA Label Image

Figure 6 (Arimidex Figuresix)

A Kaplan-Meier survival curve chart displaying the proportion of patients not experiencing disease progression over time (in months) for two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months, and the y-axis shows the proportion not progressing. A table below the chart indicates the number of patients at risk at various time points for each treatment.*

FDA Label Image

Figure 3 (Arimidex Figurethree 01)

A line chart comparing time to event (in months) and proportion event free for two treatments: Anastrozole and Tamoxifen. The chart shows survival curves over a period up to 120 months, with Anastrozole represented by a solid line and Tamoxifen by a dashed line.*

FDA Label Image

Figure 2 (Arimidex Figuretwo 01)

A survival curve chart showing disease-free survival in months on the x-axis and proportion alive and disease-free on the y-axis, comparing two treatments: anastrozole (dashed line) and tamoxifen (solid line). The chart includes a table below indicating the number of patients at risk for each treatment group at specific time points.*

FDA Label Image

Figure 4 (Arimidextablenumbercorrection Figfour)

A Kaplan-Meier survival curve chart comparing the proportion of event-free patients over time (in months) between two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). Beneath the graph, patient counts at risk are listed for each treatment group at 12-month intervals up to 120 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.